A biotechnology company focused on developing precision therapies for cancer and autoimmune diseases using proprietary technology platforms.

Hummingbird Bioscience

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. 

Sign up for our updates here: https://bit.ly/HMBDNews

Heritas Capital

Amgen Ventures

Mirae Asset Venture Investment

Pureos Bioventures

Seeds Capital

Novo Holdings

Octagon Capital Advisors

Polaris Partners

Droia Ventures

EDBI

Frazier Healthcare Partners

Kon Yew Kwek, BMBCh, DPhil, Senior Vice President of Clinical Development at Hummingbird Bioscience will share our clinical development strategy and progress at the SCRI Clinical Trials Symposium 2024 (30-31 July): https://bit.ly/3xIprzF 

Kon Yew will also participate in a panel discussing the possibilities for biotechs conducting clinical trials in Singapore. 

 31 July 2024 (Day 2)
 Time: 11 am – 12.30 pm 
 
 Organized by the Singapore Clinical Research Institute (SCRI), the two-day event aims to showcase the impact of and opportunities for clinical trials in Singapore. 
 
 #clinicaldevelopment #clinicaltrials #singapore

Hummingbird Bioscience partnered with the Children's Wishing Well to spark children’s interest in biology and conservation. In a visit to Science Centre Singapore last month, volunteers from our team accompanied ~40 children on the “Young Geneticist Trail”, for the children to learn about DNA and genetic inheritance. The children also viewed a screening of the “Jane Goodall – Reasons for Hope” documentary at the Omni-theatre. We hope the children enjoyed their day! 

#csr #scienceeducation #biology

Gary Khoo 邱思贤, VP of CMC at Hummingbird Bioscience will speak at a panel at World ADC Asia (25-27 June, Incheon, South Korea). Gary will share about how we manage our ADC production processes. The panel will discuss supply chain management of ADC components in Asia Pacific, and navigation of European and American markets. If you will be at World ADC Asia, connect with Gary at the panel discussion. 

#worldADC #ADC World ADC Event Series

Hummingbird Bioscience will present its next-generation antibody-drug conjugate capabilities (ADC) at PEGS Boston 2024 (13-17 May). 
 
For the first time, the company will present how its proprietary 4th generation ADC platform overcomes the resistance observed with earlier generation single payload ADCs. The company will also present how its proprietary Rational Antibody Discovery (RAD) platform enables epitope-directed discovery against challenging targets for optimal drug properties. 
 
Read more on the press release: https://bit.ly/3UGUYd0

This is the third year that Hummingbird Bioscience has collaborated with South West Community Development Council and People's Association to give back to the community. On 23rd and 24th February 2024, our CSR committee and volunteers packed and distributed bags of food and necessities to households in Telok Blangah. We hope that our contributions have made a positive impact on the community. 
 
The initiative is part of a larger program (Adopt @ South West) by the South West CDC, to provide well-rounded assistance in the areas of social support & wellness, education & enrichment, and home maintenance & improvement.

The Hummingbird Bioscience team will present our clinical development, CMC, and regulatory capabilities at Clinical Trials Festival Asia and Biologics Manufacturing Asia, at Marina Bay Sands Expo & Convention Centre in Singapore on 20-21 March. 
 
Carlo Polo, Senior Director of Regulatory Science, and Kon Yew Kwek, Senior Vice President of Clinical Development will present regulatory insights on Asia’s clinical trials and our approach to precision oncology. 
 
Gary Khoo, Vice President of CMC, will present the key considerations in developing and manufacturing next generation ADCs. Gary will also be on a panel discussing the Asia biomanufacturing market. 
 
IMAPAC #clinicaldevelopment #regulatoryscience #ADC

Metric
Company Name	Hummingbird Bioscience	Therini Bio	Li Lab of Computational Cancer Immunology
Symbol
MSH ID	COM:HUMMINGBIRDBIOSCIENCE	COM:THERINIBIO	ORG:LILAB-UTSW
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	SG	US	US
Stage	Series C
Employee Count	96
Website	hummingbirdbioscience.com	therinibio.com	lilab-utsw.org
LinkedIn	hummingbird-bioscience	therinibio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	4.68K
Web Traffic Growth	19.62
Valuation
Raised Capital	125M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

HUMM

COM:HUMMINGBIRDBIOSCIENCE

Hummingbird Bioscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue